The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 13, 2020
Filed:
Feb. 27, 2018
Applicant:
Leidos, Inc., Reston, VA (US);
Inventors:
Gabriel M. Gutierrez, Reston, VA (US);
Vinayaka Kotraiah, Reston, VA (US);
James Pannucci, Reston, VA (US);
Ramses Ayala, Reston, VA (US);
Assignee:
Leidos, Inc., Reston, VA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/10 (2006.01); A61K 39/015 (2006.01); A61K 38/16 (2006.01); A61K 39/00 (2006.01); A61K 35/17 (2015.01); A61K 38/19 (2006.01); A61P 33/06 (2006.01); A61P 31/20 (2006.01); A61P 37/04 (2006.01); A61P 35/04 (2006.01); A61K 45/06 (2006.01); C07K 7/08 (2006.01); C07K 14/00 (2006.01); A61K 39/39 (2006.01); A61K 48/00 (2006.01);
U.S. Cl.
CPC ...
A61K 38/10 (2013.01); A61K 35/17 (2013.01); A61K 38/16 (2013.01); A61K 38/19 (2013.01); A61K 39/0011 (2013.01); A61K 39/015 (2013.01); A61K 39/39 (2013.01); A61K 45/06 (2013.01); A61P 31/20 (2018.01); A61P 33/06 (2018.01); A61P 35/04 (2018.01); A61P 37/04 (2018.01); C07K 7/08 (2013.01); C07K 14/00 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0331 (2013.01); A01K 2267/0337 (2013.01); A61K 48/00 (2013.01);
Abstract
This disclosure provides peptides which have a strong affinity for the checkpoint receptor 'programmed death 1' (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.